Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Advances in G Protein-Coupled Receptor Allostery: From Function to Structure

Christopoulos, Arthur·2014·Molecular Pharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/mol.114.094342

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 178

  1. Abdul-Ridha, 2013, Allosteric modulation of a chemogenetically modified G protein-coupled receptor, Mol Pharmacol, 83, 521, 10.1124/mol.112.083006 · DOI
  2. Abdul-Ridha, 2014, Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor, J Biol Chem, 289, 6067, 10.1074/jbc.M113.539080 · DOI
  3. Ahn, 2012, Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation, J Biol Chem, 287, 12070, 10.1074/jbc.M111.316463 · DOI
  4. Allison, 2012, Reinventing clinical trials, Nat Biotechnol, 30, 41, 10.1038/nbt.2083 · DOI
  5. Antony, 2009, Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity, FASEB J, 23, 442, 10.1096/fj.08-114751 · DOI
  6. Aurelio, 2009, Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes, J Med Chem, 52, 4543, 10.1021/jm9002582 · DOI
  7. Avlani, 2010, Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor, Mol Pharmacol, 78, 94, 10.1124/mol.110.064345 · DOI
  8. Bauer, 2012, Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors, J Biol Chem, 287, 36944, 10.1074/jbc.M112.382481 · DOI · Paper page
  9. Black, 1983, Operational models of pharmacological agonism, Proc R Soc Lond B Biol Sci, 220, 141, 10.1098/rspb.1983.0093 · DOI · Paper page
  10. Block, 2004, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N Engl J Med, 350, 1516, 10.1056/NEJMoa031633 · DOI · Paper page
  11. Bock, 2012, The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling, Nat Commun, 3, 1044, 10.1038/ncomms2028 · DOI
  12. Bodick, 1997, The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease, Alzheimer Dis Assoc Disord, 11, S16
  13. Bono, 2013, Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties, Cancer Cell, 23, 477, 10.1016/j.ccr.2013.02.019 · DOI
  14. Borda, 1996, Circulating antibodies against neonatal cardiac muscarinic acetylcholine receptor in patients with Sjögren’s syndrome, Mol Cell Biochem, 163-164, 335, 10.1007/BF00408674 · doi:10.1007/bf00408674
  15. Bradley, 2011, Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia, Mol Pharmacol, 79, 874, 10.1124/mol.110.068882 · DOI
  16. Braestrup, 1979, Partial agonists for brain GABA/benzodiazepine receptor complex, Nature, 280, 331, 10.1038/280331a0 · DOI
  17. Broadhead, 2011, Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with l-amino acids, J Biol Chem, 286, 8786, 10.1074/jbc.M110.149724 · DOI
  18. Bruns, 1990, Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes, Mol Pharmacol, 38, 939, 10.1016/S0026-895X(25)09591-4 · DOI · Paper page
  19. Busque, 2005, l-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells, Am J Physiol Gastrointest Liver Physiol, 289, G664, 10.1152/ajpgi.00096.2005 · DOI
  20. Canals, 2012, A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation, J Biol Chem, 287, 650, 10.1074/jbc.M111.314278 · DOI
  21. Canals, 2011, Allostery in GPCRs: ‘MWC’ revisited, Trends Biochem Sci, 36, 663, 10.1016/j.tibs.2011.08.005 · DOI
  22. Catterall, 2007, Voltage-gated ion channels and gating modifier toxins, Toxicon, 49, 124, 10.1016/j.toxicon.2006.09.022 · DOI · Paper page
  23. Chan, 2008, Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia, Proc Natl Acad Sci USA, 105, 10978, 10.1073/pnas.0800567105 · DOI · Paper page
  24. Changeux, 2013, 50 years of allosteric interactions: the twists and turns of the models, Nat Rev Mol Cell Biol, 14, 819, 10.1038/nrm3695 · DOI · Paper page
  25. Cherezov, 2007, High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor, Science, 318, 1258, 10.1126/science.1150577 · DOI · Paper page
  26. Christopoulos, 2002, Allosteric binding sites on cell-surface receptors: novel targets for drug discovery, Nat Rev Drug Discov, 1, 198, 10.1038/nrd746 · DOI · Paper page
  27. Christopoulos, 2014, International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands, Pharmacol Rev, 66, 918, 10.1124/pr.114.008862 · DOI · Paper page
  28. Christopoulos, 2003, Novel receptor partners and function of receptor activity-modifying proteins, J Biol Chem, 278, 3293, 10.1074/jbc.C200629200 · DOI · Paper page
  29. Christopoulos, 2002, G protein-coupled receptor allosterism and complexing, Pharmacol Rev, 54, 323, 10.1124/pr.54.2.323 · DOI · Paper page
  30. Clark, 1976, The inhibitory effect of gallamine on muscarinic receptors, Br J Pharmacol, 58, 323, 10.1111/j.1476-5381.1976.tb07708.x · DOI · Paper page
  31. Ciolek, 2011, Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor, Eur J Pharmacol, 655, 1, 10.1016/j.ejphar.2010.12.042 · doi:10.1016/j.ejphar.2010.12.042
  32. Colquhoun, 1998, Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors, Br J Pharmacol, 125, 924, 10.1038/sj.bjp.0702164 · DOI · Paper page
  33. Conigrave, 2010, Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development, Pharmacol Ther, 127, 252, 10.1016/j.pharmthera.2010.04.007 · DOI
  34. Conigrave, 2000, l-amino acid sensing by the extracellular Ca2+-sensing receptor, Proc Natl Acad Sci USA, 97, 4814, 10.1073/pnas.97.9.4814 · DOI · Paper page
  35. Coureuil, 2010, Meningococcus hijacks a β2-adrenoceptor/β-arrestin pathway to cross brain microvasculature endothelium, Cell, 143, 1149, 10.1016/j.cell.2010.11.035 · DOI · Paper page
  36. Davey, 2012, Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor, Endocrinology, 153, 1232, 10.1210/en.2011-1426 · DOI · Paper page
  37. De Lean, 1980, A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor, J Biol Chem, 255, 7108, 10.1016/S0021-9258(20)79672-9 · DOI · Paper page
  38. De Smet F, Christopoulos A, Carmeliet P (2014) Allosteric targeting of receptor tyrosine kinases. Nat Biotechnol, in press. · DOI
  39. Disingrini, 2006, Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors, J Med Chem, 49, 366, 10.1021/jm050769s · DOI
  40. Dror, 2013, Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs, Nature, 503, 295, 10.1038/nature12595 · DOI · Paper page
  41. Ehlert, 1985, The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium, Mol Pharmacol, 28, 410, 10.1016/S0026-895X(25)14182-5 · DOI · Paper page
  42. Ehlert, 1982, Modulation of benzodiazepine receptor binding: insight into pharmacological efficacy, Eur J Pharmacol, 78, 249, 10.1016/0014-2999(82)90246-1 · doi:10.1016/0014-2999(82)90246-1
  43. Ehlert, 2005, Analysis of allosterism in functional assays, J Pharmacol Exp Ther, 315, 740, 10.1124/jpet.105.090886 · DOI · Paper page
  44. Ellis, 1992, Two allosteric modulators interact at a common site on cardiac muscarinic receptors, Mol Pharmacol, 42, 638, 10.1016/S0026-895X(25)09006-6 · doi:10.1016/s0026-895x(25)09006-6
  45. Eroglu, 2003, Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts, Proc Natl Acad Sci USA, 100, 10219, 10.1073/pnas.1737042100 · DOI
  46. Evans, 2011, Quantification of functional selectivity at the human α(1A)-adrenoceptor, Mol Pharmacol, 79, 298, 10.1124/mol.110.067454 · DOI
  47. Fenalti, 2014, Molecular control of δ-opioid receptor signalling, Nature, 506, 191, 10.1038/nature12944 · DOI · Paper page
  48. Fenton, 2008, Allostery: an illustrated definition for the ‘second secret of life’, Trends Biochem Sci, 33, 420, 10.1016/j.tibs.2008.05.009 · DOI · Paper page
  49. Ferré, 2014, G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives, Pharmacol Rev, 66, 413, 10.1124/pr.113.008052 · DOI · Paper page
  50. Figueroa, 2009, Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes, J Pharmacol Exp Ther, 328, 331, 10.1124/jpet.108.145219 · DOI
  51. Fillion, 1996, A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors, Behav Brain Res, 73, 313, 10.1016/0166-4328(96)00120-9 · doi:10.1016/0166-4328(96)00120-9
  52. Galvez, 2000, Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit, Mol Pharmacol, 57, 419, 10.1016/S0026-895X(24)26405-1 · doi:10.1016/s0026-895x(24)26405-1
  53. Gimpl, 1997, Cholesterol as modulator of receptor function, Biochemistry, 36, 10959, 10.1021/bi963138w · DOI · Paper page
  54. Goupil, 2010, A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2α-mediated Rho/ROCK signaling pathway, J Biol Chem, 285, 25624, 10.1074/jbc.M110.115196 · DOI
  55. Gregory, 2010, Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias, J Biol Chem, 285, 7459, 10.1074/jbc.M109.094011 · DOI · Paper page
  56. Gregory, 2012, Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships, Mol Pharmacol, 82, 860, 10.1124/mol.112.080531 · DOI
  57. Gurevich, 1997, Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity, J Biol Chem, 272, 28849, 10.1074/jbc.272.46.28849 · DOI · Paper page
  58. Haga, 2012, Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist, Nature, 482, 547, 10.1038/nature10753 · DOI · Paper page
  59. Hanson, 2008, A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor, Structure, 16, 897, 10.1016/j.str.2008.05.001 · DOI · Paper page
  60. Hedlund, 1999, Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors, Biochem Pharmacol, 58, 1807, 10.1016/S0006-2952(99)00274-9 · DOI
  61. Hernández, 2003, Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca2+ currents, Cardiovasc Res, 58, 55, 10.1016/S0008-6363(02)00811-8 · DOI
  62. Hollenstein, 2013, Structure of class B GPCR corticotropin-releasing factor receptor 1, Nature, 499, 438, 10.1038/nature12357 · DOI · Paper page
  63. Holst, 2002, Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors, J Biol Chem, 277, 47662, 10.1074/jbc.M202103200 · DOI
  64. Huynh, 2013, Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor, J Med Chem, 56, 8196, 10.1021/jm401032k · DOI
  65. Jacobson, 2010, The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1′-(2-methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site, Mol Pharmacol, 78, 648, 10.1124/mol.110.065771 · doi:10.1124/mol.110.065771
  66. Jacoby, 1993, Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor, J Clin Invest, 91, 1314, 10.1172/JCI116331 · DOI · Paper page
  67. Katritch, 2014, Allosteric sodium in class A GPCR signaling, Trends Biochem Sci, 39, 233, 10.1016/j.tibs.2014.03.002 · DOI · Paper page
  68. Kebig, 2009, An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators, J Recept Signal Transduct Res, 29, 140, 10.1080/10799890903047437 · DOI
  69. Kenakin, 2005, New concepts in drug discovery: collateral efficacy and permissive antagonism, Nat Rev Drug Discov, 4, 919, 10.1038/nrd1875 · DOI · Paper page
  70. Kenakin, 2013, Signalling bias in new drug discovery: detection, quantification and therapeutic impact, Nat Rev Drug Discov, 12, 205, 10.1038/nrd3954 · DOI · Paper page
  71. Kenakin, 2010, Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery, Pharmacol Rev, 62, 265, 10.1124/pr.108.000992 · DOI · Paper page
  72. Kenakin, 2012, A simple method for quantifying functional selectivity and agonist bias, ACS Chem Neurosci, 3, 193, 10.1021/cn200111m · DOI · Paper page
  73. Keov, 2011, Allosteric modulation of G protein-coupled receptors: a pharmacological perspective, Neuropharmacology, 60, 24, 10.1016/j.neuropharm.2010.07.010 · DOI · Paper page
  74. Keov, 2013, Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor, Mol Pharmacol, 84, 425, 10.1124/mol.113.087320 · DOI
  75. Kerr, 2003, Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex, Eur J Pharmacol, 468, 103, 10.1016/S0014-2999(03)01675-3 · doi:10.1016/s0014-2999(03)01675-3
  76. Koole, 2012, Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function, J Biol Chem, 287, 3659, 10.1074/jbc.M111.309369 · DOI
  77. Koole, 2010, Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening, Mol Pharmacol, 78, 456, 10.1124/mol.110.065664 · DOI · Paper page
  78. Koshland, 1966, Comparison of experimental binding data and theoretical models in proteins containing subunits, Biochemistry, 5, 365, 10.1021/bi00865a047 · DOI · Paper page
  79. Kruse, 2014, Muscarinic acetylcholine receptors: novel opportunities for drug development, Nat Rev Drug Discov, 13, 549, 10.1038/nrd4295 · DOI · Paper page
  80. Kruse, 2013, Activation and allosteric modulation of a muscarinic acetylcholine receptor, Nature, 504, 101, 10.1038/nature12735 · DOI · Paper page
  81. Lagerström, 2008, Structural diversity of G protein-coupled receptors and significance for drug discovery, Nat Rev Drug Discov, 7, 339, 10.1038/nrd2518 · DOI · Paper page
  82. Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, Lopez L, Scammells PJ, Capuano B, et al. (2014) A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol, in press. · DOI
  83. Lane, 2013, Bridging the gap: bitopic ligands of G-protein-coupled receptors, Trends Pharmacol Sci, 34, 59, 10.1016/j.tips.2012.10.003 · DOI · Paper page
  84. Langmead, 2008, Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1, Br J Pharmacol, 154, 1104, 10.1038/bjp.2008.152 · DOI
  85. Langmead, 2006, Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox, Trends Pharmacol Sci, 27, 475, 10.1016/j.tips.2006.07.009 · DOI
  86. Langmead, 2014, Functional and structural perspectives on allosteric modulation of GPCRs, Curr Opin Cell Biol, 27, 94, 10.1016/j.ceb.2013.11.007 · DOI
  87. Lazareno, 2004, Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity, Mol Pharmacol, 65, 257, 10.1124/mol.65.1.257 · DOI
  88. Leach, 2010, Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties, Neuropsychopharmacology, 35, 855, 10.1038/npp.2009.194 · DOI · Paper page
  89. Leach, 2007, Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology, Trends Pharmacol Sci, 28, 382, 10.1016/j.tips.2007.06.004 · DOI · Paper page
  90. Leach, 2012, Structure-function studies of muscarinic acetylcholine receptors, Handb Exp Pharmacol, 208, 29, 10.1007/978-3-642-23274-9_2 · DOI
  91. Leach, 2013, Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators, Endocrinology, 154, 1105, 10.1210/en.2012-1887 · DOI
  92. Leggett, 2004, Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors, Br J Pharmacol, 141, 253, 10.1038/sj.bjp.0705607 · DOI · Paper page
  93. Leiros, 1997, Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas’ disease, J Biol Chem, 272, 12989, 10.1074/jbc.272.20.12989 · doi:10.1074/jbc.272.20.12989
  94. Liou, 2011, The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to l-phenylalanine in acutely isolated intestinal I cells, Am J Physiol Gastrointest Liver Physiol, 300, G538, 10.1152/ajpgi.00342.2010 · DOI · Paper page
  95. Litschig, 1999, CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding, Mol Pharmacol, 55, 453, 10.1016/S0026-895X(24)12169-4 · DOI · Paper page
  96. Liu, 2012, Structural basis for allosteric regulation of GPCRs by sodium ions, Science, 337, 232, 10.1126/science.1219218 · DOI · Paper page
  97. Lüllmann, 1969, Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds, Eur J Pharmacol, 6, 241, 10.1016/0014-2999(69)90181-2 · DOI
  98. Ma, 2009, Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation, Proc Natl Acad Sci USA, 106, 15950, 10.1073/pnas.0900903106 · DOI · Paper page
  99. Maillet, 2007, A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties, FASEB J, 21, 2124, 10.1096/fj.06-7683com · doi:10.1096/fj.06-7683com
  100. Makita, 2007, An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations, Proc Natl Acad Sci USA, 104, 5443, 10.1073/pnas.0701290104 · DOI
  101. Marlo, 2009, Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity, Mol Pharmacol, 75, 577, 10.1124/mol.108.052886 · DOI
  102. Mary, 2012, Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor, Proc Natl Acad Sci USA, 109, 8304, 10.1073/pnas.1119881109 · DOI
  103. Massot, 1996, 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors, Mol Pharmacol, 50, 752, 10.1016/S0026-895X(25)09375-7 · DOI
  104. Mathiesen, 2005, Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2, Mol Pharmacol, 68, 393, 10.1124/mol.104.010520 · DOI
  105. May, 2007, Allosteric modulation of G protein-coupled receptors, Annu Rev Pharmacol Toxicol, 47, 1, 10.1146/annurev.pharmtox.47.120505.105159 · DOI · Paper page
  106. Melancon, 2012, Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery, J Med Chem, 55, 1445, 10.1021/jm201139r · DOI · Paper page
  107. Mistry, 2013, Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor, J Med Chem, 56, 5151, 10.1021/jm400540b · DOI
  108. Mohr, 2013, Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors, Angew Chem Int Ed Engl, 52, 508, 10.1002/anie.201205315 · DOI
  109. Mohr, 2010, Rational design of dualsteric GPCR ligands: quests and promise, Br J Pharmacol, 159, 997, 10.1111/j.1476-5381.2009.00601.x · DOI
  110. Monod, 1963, Allosteric proteins and cellular control systems, J Mol Biol, 6, 306, 10.1016/S0022-2836(63)80091-1 · DOI · Paper page
  111. Monod, 1965, On the nature of allosteric transitions: a plausible model, J Mol Biol, 12, 88, 10.1016/S0022-2836(65)80285-6 · DOI · Paper page
  112. Narlawar, 2010, Hybrid ortho/allosteric ligands for the adenosine A(1) receptor, J Med Chem, 53, 3028, 10.1021/jm901252a · DOI
  113. Nawaratne, 2010, Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms, J Biol Chem, 285, 19012, 10.1074/jbc.M110.125096 · DOI
  114. Neubig, 2003, International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology, Pharmacol Rev, 55, 597, 10.1124/pr.55.4.4 · DOI · Paper page
  115. Nussinov, 2013, Allostery in disease and in drug discovery, Cell, 153, 293, 10.1016/j.cell.2013.03.034 · DOI · Paper page
  116. Olsen, 2004, Fishing for allosteric sites on GABA(A) receptors, Biochem Pharmacol, 68, 1675, 10.1016/j.bcp.2004.07.026 · DOI
  117. Onaran, 2012, Where have all the active receptor states gone?, Nat Chem Biol, 8, 674, 10.1038/nchembio.1024 · doi:10.1038/nchembio.1024
  118. Pamplona, 2012, Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor, Proc Natl Acad Sci USA, 109, 21134, 10.1073/pnas.1202906109 · DOI · Paper page
  119. Parmentier-Batteur, 2014, Mechanism based neurotoxicity of mGlu5 positive allosteric modulators—development challenges for a promising novel antipsychotic target, Neuropharmacology, 82, 161, 10.1016/j.neuropharm.2012.12.003 · DOI
  120. Pasternak, 1975, Selective enhancement of [3H]opiate agonist binding by divalent cations, Mol Pharmacol, 11, 735, 10.1016/S0026-895X(25)10670-6 · doi:10.1016/s0026-895x(25)10670-6
  121. Pert, 1973, Opiate agonists and antagonists discriminated by receptor binding in brain, Science, 182, 1359, 10.1126/science.182.4119.1359 · DOI · Paper page
  122. Potter, 2012, Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol, J Lipid Res, 53, 137, 10.1194/jlr.M020065 · DOI
  123. Prasad, 2009, Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells, Biochem Biophys Res Commun, 390, 93, 10.1016/j.bbrc.2009.09.072 · DOI
  124. Price, 2005, Allosteric modulation of the cannabinoid CB1 receptor, Mol Pharmacol, 68, 1484, 10.1124/mol.105.016162 · DOI · Paper page
  125. Rajagopal, 2011, Quantifying ligand bias at seven-transmembrane receptors, Mol Pharmacol, 80, 367, 10.1124/mol.111.072801 · DOI · Paper page
  126. Reiter, 2012, Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors, Annu Rev Pharmacol Toxicol, 52, 179, 10.1146/annurev.pharmtox.010909.105800 · DOI · Paper page
  127. Rodriguez, 1992, Differential effects of Mg2+ and other divalent cations on the binding of tritiated opioid ligands, J Neurochem, 59, 467, 10.1111/j.1471-4159.1992.tb09393.x · DOI
  128. Rominger, 2009, Evidence for allosteric interactions of antagonist binding to the smoothened receptor, J Pharmacol Exp Ther, 329, 995, 10.1124/jpet.109.152090 · DOI
  129. Rosenbaum, 2011, Structure and function of an irreversible agonist-β(2) adrenoceptor complex, Nature, 469, 236, 10.1038/nature09665 · DOI · Paper page
  130. Rousselle, 1996, Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes, J Biol Chem, 271, 726, 10.1074/jbc.271.2.726 · DOI
  131. Schetz, 1997, Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors, J Neurochem, 68, 1990, 10.1046/j.1471-4159.1997.68051990.x · doi:10.1046/j.1471-4159.1997.68051990.x
  132. Schetz, 2001, The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation, J Pharmacol Exp Ther, 296, 359, 10.1016/S0022-3565(24)38793-2 · doi:10.1016/s0022-3565(24)38793-2
  133. Shirey, 2009, A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning, J Neurosci, 29, 14271, 10.1523/JNEUROSCI.3930-09.2009 · DOI · Paper page
  134. Shonberg, 2013, A structure-activity analysis of biased agonism at the dopamine D2 receptor, J Med Chem, 56, 9199, 10.1021/jm401318w · DOI
  135. Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, Lane JR (2014) Biased agonism at G protein-coupled receptors: the promise and the challenges—a medicinal chemistry perspective. Med Res Rev. DOI: 10.1002/med.21318 [published ahead of print] · DOI
  136. Silvano, 2010, The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors, Mol Pharmacol, 78, 925, 10.1124/mol.110.065755 · DOI
  137. Simon, 1975, Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions, Proc Natl Acad Sci USA, 72, 2404, 10.1073/pnas.72.6.2404 · DOI
  138. Smith, 2010, Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes, Pharmacol Rev, 62, 701, 10.1124/pr.110.002667 · DOI · Paper page
  139. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. DOI: 10.1016/j.pain.2014.06.011 [published ahead of print] · DOI · Paper page
  140. Spalding, 2002, Discovery of an ectopic activation site on the M(1) muscarinic receptor, Mol Pharmacol, 61, 1297, 10.1016/S0026-895X(24)12088-3 · DOI · Paper page
  141. Spedding, 1995, New drug binding sites in Ca2+ channels, Trends Pharmacol Sci, 16, 139, 10.1016/S0165-6147(00)89002-1 · doi:10.1016/s0165-6147(00)89002-1
  142. Spedding, 1987, Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand, Br J Pharmacol, 92, 457, 10.1111/j.1476-5381.1987.tb11343.x · doi:10.1111/j.1476-5381.1987.tb11343.x
  143. Stallaert, 2011, Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors, Expert Opin Drug Discov, 6, 811, 10.1517/17460441.2011.586691 · DOI
  144. Steinfeld, 2007, A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor, Mol Pharmacol, 72, 291, 10.1124/mol.106.033746 · DOI
  145. Sterin-Borda, 1999, Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies, Cardiovasc Res, 41, 116, 10.1016/S0008-6363(98)00225-9 · doi:10.1016/s0008-6363(98)00225-9
  146. Stewart, 2010, Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae, Mol Pharmacol, 78, 205, 10.1124/mol.110.064253 · DOI
  147. Stockton, 1983, Modification of the binding properties of muscarinic receptors by gallamine, Mol Pharmacol, 23, 551, 10.1016/S0026-895X(25)14327-7 · DOI · Paper page
  148. Suratman, 2011, Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor, Br J Pharmacol, 162, 1659, 10.1111/j.1476-5381.2010.01184.x · DOI
  149. Swaminath, 2003, Identification of an allosteric binding site for Zn2+ on the β2 adrenergic receptor, J Biol Chem, 278, 352, 10.1074/jbc.M206424200 · DOI
  150. Swaminath, 2002, Allosteric modulation of β2-adrenergic receptor by Zn(2+), Mol Pharmacol, 61, 65, 10.1124/mol.61.1.65 · DOI
  151. Szabo, 2014, Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor, J Med Chem, 57, 4924, 10.1021/jm500457x · DOI
  152. Taly, 2009, Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system, Nat Rev Drug Discov, 8, 733, 10.1038/nrd2927 · DOI · Paper page
  153. Tan, 2013, Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex, Science, 341, 1387, 10.1126/science.1241475 · DOI · Paper page
  154. Thomas, 1997, Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide, Proc Natl Acad Sci USA, 94, 14115, 10.1073/pnas.94.25.14115 · DOI
  155. Thomas, 1998, Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling, Ann N Y Acad Sci, 861, 183, 10.1111/j.1749-6632.1998.tb10190.x · DOI
  156. Thompson, 2008, G protein-coupled receptors disrupted in human genetic disease, Methods Mol Biol, 448, 109, 10.1007/978-1-59745-205-2_7 · DOI
  157. Tränkle, 1998, Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors, Mol Pharmacol, 54, 139, 10.1124/mol.54.1.139 · doi:10.1124/mol.54.1.139
  158. Tschammer, 2011, Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor, Mol Pharmacol, 79, 575, 10.1124/mol.110.068106 · DOI
  159. Tschammer, 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions, J Med Chem, 54, 2477, 10.1021/jm101639t · DOI
  160. Urban, 2007, Functional selectivity and classical concepts of quantitative pharmacology, J Pharmacol Exp Ther, 320, 1, 10.1124/jpet.106.104463 · DOI · Paper page
  161. Valant, 2012, Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor, J Med Chem, 55, 2367, 10.1021/jm201600e · DOI
  162. Valant, 2010, Delineating the mode of action of adenosine A1 receptor allosteric modulators, Mol Pharmacol, 78, 444, 10.1124/mol.110.064568 · DOI
  163. Valant, 2012, Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects, Mol Pharmacol, 81, 41, 10.1124/mol.111.074872 · DOI
  164. Valant, 2008, A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand, J Biol Chem, 283, 29312, 10.1074/jbc.M803801200 · DOI · Paper page
  165. Valant, 2014, Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist, Proc Natl Acad Sci USA, 111, 4614, 10.1073/pnas.1320962111 · DOI
  166. Valant, 2012, The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors, Annu Rev Pharmacol Toxicol, 52, 153, 10.1146/annurev-pharmtox-010611-134514 · DOI · Paper page
  167. Valant, 2009, Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs, Mol Interv, 9, 125, 10.1124/mi.9.3.6 · DOI
  168. Vallée, 2014, Pregnenolone can protect the brain from cannabis intoxication, Science, 343, 94, 10.1126/science.1243985 · DOI · Paper page
  169. van der Westhuizen, 2014, Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy, Mol Pharmacol, 85, 492, 10.1124/mol.113.088880 · DOI · Paper page
  170. Varney, 1999, SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5, J Pharmacol Exp Ther, 290, 170, 10.1016/S0022-3565(24)34881-5 · DOI · Paper page
  171. Verbout, 2007, Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism, Am J Physiol Lung Cell Mol Physiol, 292, L1126, 10.1152/ajplung.00455.2006 · DOI
  172. Violin, 2014, Biased ligands at G-protein-coupled receptors: promise and progress, Trends Pharmacol Sci, 35, 308, 10.1016/j.tips.2014.04.007 · DOI · Paper page
  173. Wang, 2014, Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs, Nature Comm, 5, 4355, 10.1038/ncomms5355 · DOI · Paper page
  174. Wenthur, 2014, Drugs for allosteric sites on receptors, Annu Rev Pharmacol Toxicol, 54, 165, 10.1146/annurev-pharmtox-010611-134525 · DOI · Paper page
  175. Williams, 1978, Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors, J Biol Chem, 253, 2984, 10.1016/S0021-9258(17)40792-7 · doi:10.1016/s0021-9258(17)40792-7
  176. Wootten, 2012, Allosteric modulation of endogenous metabolites as an avenue for drug discovery, Mol Pharmacol, 82, 281, 10.1124/mol.112.079319 · DOI
  177. Wu, 2014, Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator, Science, 344, 58, 10.1126/science.1249489 · DOI · Paper page
  178. Zhang, 2005, Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes, J Pharmacol Exp Ther, 315, 1212, 10.1124/jpet.105.090308 · DOI

Cited by

See all 220

Metadata

Authors
Christopoulos, A.
Venue
Molecular Pharmacology
Publisher
Elsevier BV
Published
2014-11
Volume
86
Issue
5
Pages
463-478
ISSN
0026-895X (ISSN-L)
OpenAlex
W2050650917
Cited by
220
References
12
FWCI
9.00
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in G Protein-Coupled Receptor Allostery: From Function to Structure. https://app.cochat.ai/papers/10.1124/mol.114.094342
The paper
Christopoulos, A. (2014). Advances in G Protein-Coupled Receptor Allostery: From Function to Structure. Molecular Pharmacology. https://doi.org/10.1124/mol.114.094342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.